Essex LLC Buys 21,179 Shares of Danaher Corporation $DHR

Essex LLC bought a new stake in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 21,179 shares of the conglomerate’s stock, valued at approximately $4,692,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cultivar Capital Inc. purchased a new stake in Danaher in the third quarter valued at approximately $619,000. Orca Wealth Management LLC lifted its holdings in shares of Danaher by 159.3% in the 3rd quarter. Orca Wealth Management LLC now owns 7,164 shares of the conglomerate’s stock valued at $1,587,000 after buying an additional 4,401 shares during the period. Triumph Capital Management boosted its stake in shares of Danaher by 409.6% in the third quarter. Triumph Capital Management now owns 846 shares of the conglomerate’s stock worth $187,000 after buying an additional 680 shares during the last quarter. Consilium Wealth Advisory LLC purchased a new position in Danaher during the third quarter valued at approximately $580,000. Finally, Investment Planning Advisors Inc. acquired a new position in Danaher in the third quarter valued at approximately $2,540,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. TD Cowen lifted their price target on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday. Wells Fargo & Company dropped their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. UBS Group began coverage on shares of Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price on the stock. Guggenheim boosted their target price on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Finally, The Goldman Sachs Group lifted their target price on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $235.41.

Danaher Stock Performance

Shares of NYSE DHR traded up $1.81 during midday trading on Wednesday, reaching $224.65. 3,595,884 shares of the company were exchanged, compared to its average volume of 4,457,645. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a market cap of $157.93 billion, a P/E ratio of 39.90, a PEG ratio of 2.78 and a beta of 0.76. The stock has a fifty day simple moving average of $212.41 and a 200 day simple moving average of $195.13. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the previous year, the business earned $0.77 earnings per share. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. On average, research analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s payout ratio is 28.42%.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.